Merck & Co. (MRK)
(Real Time Quote from BATS)
$124.98 USD
-0.39 (-0.31%)
Updated Apr 18, 2024 12:14 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Average Brokerage Rating
Current ABR | 1.42 |
ABR (Last week) | 1.42 |
# of Recs in ABR | 24 |
Average Target Price | $133.13 |
LT Growth Rate | 9.00% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 201 of 252 |
Current Quarter EPS Est: | 2.01 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 20 | 20 | 19 | 19 | 18 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 0 | 0 |
ABR | 1.42 | 1.42 | 1.43 | 1.27 | 1.29 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/8/2024 | Berenberg Bank | Luisa Hector | Strong Buy | Strong Buy |
3/28/2024 | Truist Securities | Robyn Karnauskas | Strong Buy | Strong Buy |
3/12/2024 | Societe Generale | Justin S Smith | Not Available | Strong Sell |
2/29/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
2/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/29/2024 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
10/27/2023 | BMO Capital Markets | Evan Seigerman | Not Available | Strong Buy |
10/17/2023 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
8/7/2023 | Daiwa America | Narumi Nakagiri | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.